ArticleOncology letters2019
Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review.Frontiers in oncology · 2025Pooled it
- Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Pooled it
- A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors.Frontiers in oncology · 2023Pooled it
- Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.Frontiers in immunology · 2023Pooled it
- Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients.Frontiers in oncology · 2022Pooled it
- An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.Oncoimmunology · 2021Pooled it
- The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies.Cancer immunology, immunotherapy : CII · 2020Pooled it
- Harnessing the microbiome: a new frontier in lung cancer immunotherapy.Cancer biology & medicine · 2026Review
- Antibiotics and probiotics differentially shape immunotherapy outcomes in non-small cell lung cancer.Cancer biology & medicine · 2026Article
- Antibiotic exposure impairs the efficacy of first-line chemoimmunotherapy in non-small cell lung cancer through the regulation of gut microbiome and bile acid metabolism.Precision clinical medicine · 2026Article
- Article
- The gut resistome as a potential determinant of immunotherapy response: antibiotics, immunometabolism, and precision oncology.Frontiers in microbiology · 2026Review
- Real-world effectiveness of first-line immunotherapy with or without chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer.Frontiers in immunology · 2026Article
- The double-edged sword: impact of antibiotic use on immunotherapy efficacy in advanced hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Research status of the relationship between microecological imbalance and lung cancer.Frontiers in microbiology · 2025Review
- Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance.Combinatorial chemistry & high throughput screening · 2025Review
- Antibiotic Usage During Surgery may be Correlated With Survival in Radically Resected Non-Small-Cell Lung Cancer Patients.Clinical Medicine Insights. Oncology · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota serves an important role in shaping systemic immune responses. Antibiotics cause changes in the gut microbiota that may influence the efficacy of cancer immunotherapy. In the present study, a retrospective analysis of the data from 90 patients treated with nivolumab for non-small cell lung cancer (NSCLC) was conducted. A total of 13 patients were treated with antibiotics prior to nivolumab therapy. The median progression-free survival time in patients treated with antibiotics was 1.2 months [95% confidence interval (CI), 0.5-5.8], while the time for patients who were not treated with antibiotics was 4.4 months (95% CI, 2.5-7.4). The median overall survival time in patients treated with antibiotics was 8.8 months, while it was not reached in those not treated with antibiotics, respectively. The differences between the survival curves with regard to PFS and OS were statistically significant (P=0.04 and P=0.037, respectively). However, in multivariate analysis, no statistically significant association was indicated between survival and prior antibiotic use, although a certain trend concerning the negative influence of antibiotic use was conveyed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.